A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk
Dimitri Stylemans, Silke François, Stefanie Vincken, Sylvia Verbanck, Eef Vanderhelst
Topics & Concepts
IvacaftorMedicineCystic fibrosisDrugLiver injuryInternal medicineCystic fibrosis transmembrane conductance regulatorPharmacologyCystic Fibrosis Research AdvancesPharmaceutical studies and practicesAmino Acid Enzymes and Metabolism